Update shared on 25 Nov 2025
Fair value Increased 7.59%Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.
Valuation Changes
- Consensus Analyst Price Target increased from THB 32.14 to THB 34.58, reflecting higher valuation expectations.
- Discount Rate edged up marginally from 7.42% to 7.44%.
- Revenue Growth forecast rose from 3.26% to 4.56%.
- Net Profit Margin estimate improved slightly from 16.14% to 16.23%.
- Future P/E ratio increased from 13.64x to 14.19x. This indicates higher anticipated earnings multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.